A Safety and Efficacy Study of NNZ-2566 in Patients With Mild Traumatic Brain Injury (mTBI)

Status:
Terminated

Trial end date:
2016-06-01

Target enrollment:

Participant gender:

The purpose of this study is to determine whether NNZ-2566 is safe and well tolerated in the treatment of mTBI in adolescents and adults.

Phase 2

Neuren Pharmaceuticals Limited

Pharmaceutical Solutions